FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981304319> ?p ?o ?g. }

• W2981304319 abstract "Abstract Background Parkinson’s disease (PD) is a slowly progressive neurodegenerative disease. There are mixed reports on success of physiotherapy in patients with PD. Our objective was to investigate the functional improvements, motivation aspects and clinical effectiveness when using immersive 3D virtual reality versus non-immersive 2D exergaming. Methods We designed a randomized parallel study with 97 patients, but only 20 eligible participants were randomized in 2 groups; the one using 3D Oculus Rift CV1 and the other using a laptop. Both groups participated in the 10-session 3 weeks training with a pick and place task in the virtual world requiring precise hand movement to manipulate the virtual cubes. The kinematics of the hand was traced with Leap motion controller, motivation effect was assessed with modified Intrinsic Motivation Inventory and clinical effectiveness was evaluated with Box & Blocks Test (BBT) and shortened Unified Parkinson’s disease rating scale (UPDRS) before and after the training. Mack-Skilling non-parametrical statistical test was used to identify statistically significant differences ( p < 0.05) and Cohen’s U3 test to find the effect sizes. Results Participants in the 3D group demonstrated statistically significant and substantially better performance in average time of manipulation (group x time, p = 0.009), number of successfully placed cubes (group x time, p = 0.028), average tremor (group x time, p = 0.002) and UPDRS for upper limb (U3 = 0.35). The LCD and 3D groups substantially improved their BBT score with training (U3 = 0.7, U3 = 0.6, respectively). However, there were no statistically significant differences in clinical tests between the groups (group x time, p = 0.2189, p = 0.2850, respectively). In addition the LCD group significantly decreased the pressure/tension (U3 = 0.3), the 3D did not show changes (U3 = 0.5) and the differences between the groups were statistically different ( p = 0.037). The 3D group demonstrated important increase in effort (U3 = 0.75) and perceived competences (U3 = 0.9). Conclusions The outcomes of the study demonstrated that the immersive 3D technology may bring increased interests/enjoyment score resulting in faster and more efficient functional performance. But the 2D technology demonstrated lower pressure/tension score providing similar clinical progress. A study with much larger sample size may also confirm the clinical effectiveness of the approaches. Trial registration The small scale randomized pilot study has been registered at ClinicalTrials.gov Identifier: NCT03515746 , 4 May 2018" @default.
• W2981304319 created "2019-10-25" @default.
• W2981304319 creator A5021069893 @default.
• W2981304319 creator A5051946425 @default.
• W2981304319 date "2019-10-17" @default.
• W2981304319 modified "2023-10-17" @default.
• W2981304319 title "Advantages of using 3D virtual reality based training in persons with Parkinson’s disease: a parallel study" @default.
• W2981304319 cites W1736815781 @default.
• W2981304319 cites W1807025324 @default.
• W2981304319 cites W190748405 @default.
• W2981304319 cites W1977086599 @default.
• W2981304319 cites W1984469627 @default.
• W2981304319 cites W1988350221 @default.
• W2981304319 cites W1989387183 @default.
• W2981304319 cites W2004687283 @default.
• W2981304319 cites W2018204822 @default.
• W2981304319 cites W2030589082 @default.
• W2981304319 cites W2039664444 @default.
• W2981304319 cites W2040239931 @default.
• W2981304319 cites W2053091365 @default.
• W2981304319 cites W2088302762 @default.
• W2981304319 cites W2097774465 @default.
• W2981304319 cites W2103129377 @default.
• W2981304319 cites W2111583069 @default.
• W2981304319 cites W2115375665 @default.
• W2981304319 cites W2126008330 @default.
• W2981304319 cites W2143375770 @default.
• W2981304319 cites W2148521360 @default.
• W2981304319 cites W2150454725 @default.
• W2981304319 cites W2152239900 @default.
• W2981304319 cites W2152399360 @default.
• W2981304319 cites W2161663931 @default.
• W2981304319 cites W2548566420 @default.
• W2981304319 cites W2560429321 @default.
• W2981304319 cites W2590558032 @default.
• W2981304319 cites W2592469439 @default.
• W2981304319 cites W2600194834 @default.
• W2981304319 cites W2600667840 @default.
• W2981304319 cites W2604815664 @default.
• W2981304319 cites W2742290178 @default.
• W2981304319 cites W2886133902 @default.
• W2981304319 cites W2898351579 @default.
• W2981304319 cites W2912877598 @default.
• W2981304319 cites W2919569345 @default.
• W2981304319 cites W4249888301 @default.
• W2981304319 doi "https://doi.org/10.1186/s12984-019-0601-1" @default.
• W2981304319 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6798369" @default.
• W2981304319 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31623622" @default.
• W2981304319 hasPublicationYear "2019" @default.
• W2981304319 type Work @default.
• W2981304319 sameAs 2981304319 @default.
• W2981304319 citedByCount "61" @default.
• W2981304319 countsByYear W29813043192020 @default.
• W2981304319 countsByYear W29813043192021 @default.
• W2981304319 countsByYear W29813043192022 @default.
• W2981304319 countsByYear W29813043192023 @default.
• W2981304319 crossrefType "journal-article" @default.
• W2981304319 hasAuthorship W2981304319A5021069893 @default.
• W2981304319 hasAuthorship W2981304319A5051946425 @default.
• W2981304319 hasBestOaLocation W29813043191 @default.
• W2981304319 hasConcept C111919701 @default.
• W2981304319 hasConcept C136764020 @default.
• W2981304319 hasConcept C138496976 @default.
• W2981304319 hasConcept C141071460 @default.
• W2981304319 hasConcept C142724271 @default.
• W2981304319 hasConcept C151730666 @default.
• W2981304319 hasConcept C154945302 @default.
• W2981304319 hasConcept C15744967 @default.
• W2981304319 hasConcept C168563851 @default.
• W2981304319 hasConcept C1862650 @default.
• W2981304319 hasConcept C194969405 @default.
• W2981304319 hasConcept C2777267654 @default.
• W2981304319 hasConcept C2779134260 @default.
• W2981304319 hasConcept C2779182362 @default.
• W2981304319 hasConcept C2779734285 @default.
• W2981304319 hasConcept C2780008327 @default.
• W2981304319 hasConcept C41008148 @default.
• W2981304319 hasConcept C71924100 @default.
• W2981304319 hasConcept C83849319 @default.
• W2981304319 hasConcept C86803240 @default.
• W2981304319 hasConcept C99508421 @default.
• W2981304319 hasConceptScore W2981304319C111919701 @default.
• W2981304319 hasConceptScore W2981304319C136764020 @default.
• W2981304319 hasConceptScore W2981304319C138496976 @default.
• W2981304319 hasConceptScore W2981304319C141071460 @default.
• W2981304319 hasConceptScore W2981304319C142724271 @default.
• W2981304319 hasConceptScore W2981304319C151730666 @default.
• W2981304319 hasConceptScore W2981304319C154945302 @default.
• W2981304319 hasConceptScore W2981304319C15744967 @default.
• W2981304319 hasConceptScore W2981304319C168563851 @default.
• W2981304319 hasConceptScore W2981304319C1862650 @default.
• W2981304319 hasConceptScore W2981304319C194969405 @default.
• W2981304319 hasConceptScore W2981304319C2777267654 @default.
• W2981304319 hasConceptScore W2981304319C2779134260 @default.
• W2981304319 hasConceptScore W2981304319C2779182362 @default.
• W2981304319 hasConceptScore W2981304319C2779734285 @default.
• W2981304319 hasConceptScore W2981304319C2780008327 @default.
• W2981304319 hasConceptScore W2981304319C41008148 @default.
• W2981304319 hasConceptScore W2981304319C71924100 @default.
• W2981304319 hasConceptScore W2981304319C83849319 @default.

• next